Callio Therapeutics is focused on developing next-generation multi-payload antibody-drug conjugates that deliver combinations of payloads to tumor cells. Its lead program is a HER2-targeted dual-payload ADC, and the company also plans a second undisclosed ADC program. The company was created by Frazier Life Sciences and is headquartered in Seattle and Singapore. Callio in-licensed multi-payload ADC technology and associated IP from Hummingbird Bioscience under an exclusive worldwide agreement that includes equity, potential milestone payments and royalties. Management includes executives with backgrounds at ProfoundBio, Silverback Therapeutics, SeaGen, Medarex, Hummingbird Bioscience and Genentech. The company intends to use proceeds from its recent financing to achieve clinical proof-of-concept for its pipeline.

Total raised

$187M

Funding rounds

1

Latest round

Series A

Latest activity

Mar 2025